Biotech / Finance

BeyondSpring Lead Asset Plinabulin's Anti-Cancer Mechanism Accepted for Poster Presentation at the 2017 Keystone Symposia in British Columbia

From Biotech
March 20, 2017 - 8:30am
NEW YORK, March 20, 2017 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ:BYSI), a global clinical stage biopharmaceutical company focused on the development of innovative cancer therapies, today announced that an abstract on the molecular action describing the immunological involvement in the anti-cancer effect of BeyondSpring's lead asset, Plinabulin, has been accepted for poster presentation at this year's Keystone Symposia's "Cancer Immunology and Immunotherapy: Taking a Place in Mainstream Oncology" meeting in Whistler, British Columbia, Canada. A PDF accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/c188cf35-3e58-4b00-8e0f-189de581826d The poster, which is the result of an international collaboration of over two years between BeyondSpring and the University of Basel, will be presented during the evening of Tuesday, March 21, 2017, at the Fairmont Chateau Whistler. BeyondSpring is advancing Plinabulin, a small molecule that alters the tumor micro-environment and stimulates dendritic cell maturation and T-cell activation, into a global Phase 3 clinical trial for non-small cell lung cancer (NSCLC) treatment and global Phase 2/3 clinical trial for Neutropenia prevention. Plinabulin inhibits alpha and beta Tubulin from polymerization, clearly shown in a recently solved crystal structure, with a differentiated mechanism of action compared to other Tubulin-targeting agents. By disrupting microtubules, Plinabulin potently activates GEF-H1, which allows it to further promote immune-enhancing effects in subsequent signaling pathways in the cell, with broad anti-cancer applications. The poster highlights the difference between Plinabulin and Tubulin stabilizing agents, such as the taxanes, as the latter do not release GEF-H1 and do not induce the immune-oncology ...Full story available on Benzinga.com


Continue reading this article »